share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax製藥 | 8-K:重大事件
美股SEC公告 ·  09/17 16:15

Moomoo AI 已提取核心訊息

Virpax Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol VRPX, filed a Form 8-K report with the United States Securities and Exchange Commission on September 16, 2024. The report announced the immediate resignation of Dr. Vanila M. Singh from the company's Board of Directors. Dr. Singh's departure from the board was effective as of the date of the report. The company has not provided any further details regarding the resignation or any plans for a successor.
Virpax Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol VRPX, filed a Form 8-K report with the United States Securities and Exchange Commission on September 16, 2024. The report announced the immediate resignation of Dr. Vanila M. Singh from the company's Board of Directors. Dr. Singh's departure from the board was effective as of the date of the report. The company has not provided any further details regarding the resignation or any plans for a successor.
Virpax Pharmaceuticals, Inc.是一家註冊於特拉華州的公司,在納斯達克資本市場上市,交易標的爲VRPX,於2024年9月16日向美國證券交易委員會提交了8-k表格報告。報告宣佈Vanila M. Singh博士立即辭去公司董事會成員的職務。Singh博士從董事會的離職日期即報告日起生效。公司未就辭職或任何接班人計劃提供進一步詳細信息。
Virpax Pharmaceuticals, Inc.是一家註冊於特拉華州的公司,在納斯達克資本市場上市,交易標的爲VRPX,於2024年9月16日向美國證券交易委員會提交了8-k表格報告。報告宣佈Vanila M. Singh博士立即辭去公司董事會成員的職務。Singh博士從董事會的離職日期即報告日起生效。公司未就辭職或任何接班人計劃提供進一步詳細信息。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息